相关实验视频

Updated: Jan 14, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

17α-基酶缺乏与新型CYP17A1突变:一个病例报告

Jin B Li¹, Ya Xiao¹, Shu Q Jiang¹

¹Department of Pediatric Endocrinology, Genetics and Metabolism, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Translational pediatrics

|October 27, 2025

概括

17α-基酶缺乏 (17-OHD) 是一种罕见的先天性上腺增生症,由于细微的症状,在诊断方面存在挑战. 这一案例凸显了早期激素和遗传测试对于儿童的准确鉴定和管理的重要性.

科学领域:

内分泌学在内分泌学.
遗传学是一个遗传学.
儿科儿科儿科

背景情况:

17α-基酶缺陷 (17-OHD) 是最罕见的先天性上腺增生症 (CAH) 的亚型,由CYP17A1酶缺陷引起.
它会损害皮质醇和性激素的合成,导致低血,耐药高血压和性幼儿主义.
微妙的青春期前症状可能会推迟诊断.

研究的目的:

为了记录一个患有17-OHD的青春期前儿童的临床过程.
详细说明诊断过程,包括遗传分析.
报告治疗开始和24个月后续的结果.

主要方法:

复发性高血压,低血和呼吸道感染的临床表现.
激素检测显示孕激素升高,无法检测的皮质醇和性激素降低.
基因分析证实CYP17A1化合物的异构变体,包括一种新突变 (c.1082T>C:p.L361P).

主要成果:

通过特有的荷尔蒙特征和CYP17A1突变来证实17-OHD的诊断.
治疗包括皮,美托普罗罗尔,卡普托普利和补充剂.
24个月的随访发现了新发作的心律失常和非自身免疫性甲状腺功能障碍.

结论:

17-OHD可以呈现非特异性症状,如高血压和感染,导致误诊.
早期的荷尔蒙测试 (孕激素,皮质醇) 和CYP17A1基因分析对于诊断至关重要.
鉴定一种新的CYP17A1突变扩大了17-OHD的已知遗传谱.

关键词:

17α-基酶缺乏 (17-OHD) 的情况案例报告案例报告孩子孩子孩子孩子孩子孩子基因诊断基因诊断是一种基因诊断.这是一种新的CYP17A1突变.

更多相关视频

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

相关概念视频

Cystic Fibrosis: Pathogenesis

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

Allosteric Proteins-ATCase

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...